Merck’s fast-ascending kidney cancer drug hits a setback
BioPharma Dive
Welireg s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.
pharminent
April 21, 2026 (Last updated: April 22, 2026)
BioPharma Dive
Welireg s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.
